Tirzepatide(30 mg)
Same TZ research compound in a mid-strength option for ongoing non-clinical research applications.
Mechanism of action
Tirzepatide is a dual GIP/GLP-1 receptor agonist. Published literature describes its activity at both incretin receptors and effects on glucose-dependent insulin secretion, gastric emptying, and food-intake regulation in research and clinical settings. This is the same molecule as the 60 mg configuration, supplied in a 30 mg vial for mid-strength research preparations.
Tirzepatide activates two gut-hormone receptors at the same time — the same signals your body normally sends after a meal to release insulin, slow digestion, and reduce appetite. Doing both together produced larger effects in studies than activating either one alone. This vial holds the same compound as the 60 mg version, just at a smaller total amount per vial.
Research areas
- · How the brain decides you're full
- · How gut hormones tell the pancreas to release insulin
- · How fat and lean mass change over time
History & discovery
Discovered at Eli Lilly and first described in the early 2010s, tirzepatide became the first commercially studied dual GIP/GLP-1 agonist. Major clinical trials (SURPASS and SURMOUNT series) began publishing in 2021–2022. The 30 mg vial size is identical material to the 60 mg listing.
Reconstitution & handling
Lyophilized peptides are typically reconstituted with bacteriostatic water and stored refrigerated after reconstitution. Use the dosing calculator to work out concentrations for your research preparation.
Open reconstitution calculatorAssay & QC notes
Each lot is tested by reversed-phase HPLC for purity, confirmed by mass spectrometry for identity, and screened for endotoxin contamination.